Mr. Layman joins as an independent director as the company continues to accelerate development of its antibody technology targeting persistent bacterial infections

COLUMBUS, Ohio – May 18, 2021 – Clarametyx Biosciences Inc. (“Clarametyx”), a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced the appointment of Michael Layman to the Company’s Board of Directors (BOD) as part of the Company’s latest $8 million convertible funding round.

“We welcome Michael to our growing board as we continue to build momentum in our preclinical development and work toward entry into clinical trials in the coming year,” said David Richards, Chief Executive Officer. “We believe Michael brings relevant and valued experience within the financial industry that will help shape our near-term capital strategy.”

Mr. Layman currently serves as General Partner and CEO of Emerald Shoals Targeted Opportunities Fund LP, a hybrid growth fund backed by a network of ultra-high net worth individuals seeking novel opportunities to invest in high-growth catalyst driven companies. Mr. Layman also is the co-founder and manager of Lf Athens Capital, a Delaware series LLC that seeks to provide attractive investment opportunities in private and small cap public companies, and serves as an Independent Director for American Resources Corporation (NASDAQ: AREC). He was also recently appointed as an independent director on the Land Betterment Corporation Board of Directors. Mr. Layman obtained his Bachelor of Arts degree in business from Otterbein University.

“The compelling scientific strategy and clear purpose of the expert team attracted me to the Clarametyx organization, and I look forward to bringing my expertise to support such a worthy mission,” said Mr. Layman.

About Clarametyx Biosciences

Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response or antibiotic intervention. The Columbus, Ohio-based company is building a dynamic pipeline of immune-enabling therapies and vaccines for life-threatening bacterial infections associated with biofilms. Its lead candidate, CMTX-101, is a humanized monoclonal antibody in preclinical development for moderate-to-severe pneumonia. For more information, visit us on the web or on LinkedIn.

Media Contact:

Kellie Hotz
khotz@clarametyx.com
+1-703-887-6242

# # #